Zacks Investment Research Downgrades Recordati (NASDAQ:RCDTF) to Hold
Zacks Investment Research cut shares of Recordati (NASDAQ:RCDTF) from a strong-buy rating to a hold rating in a report published on Wednesday morning.
According to Zacks, “Recordati S.p.A. is a pharmaceutical company. It engaged in the research, development, manufacturing and marketing of pharmaceuticals for rare disease treatments. The company operates primarily in Russia, Turkey, North Africa and United States of America. Recordati S.p.A. is headquartered in Milan, Italy. “
Shares of Recordati (NASDAQ:RCDTF) opened at 41.49 on Wednesday. The firm’s 50 day moving average is $41.49 and its 200 day moving average is $34.45. The stock has a market capitalization of $8.53 billion and a price-to-earnings ratio of 29.81. Recordati has a 52-week low of $23.90 and a 52-week high of $41.49.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recordati Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati and related companies with Analyst Ratings Network's FREE daily email newsletter.